Novel absorbance peak of gentisic acid following the oxidation reaction.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 26 09 2019
accepted: 10 04 2020
entrez: 30 4 2020
pubmed: 30 4 2020
medline: 29 7 2020
Statut: epublish

Résumé

Gentisic acid (GA), a metabolite of acetylsalicylic acid (ASA), and homogentisic acid (HGA), which is excreted at high levels in alkaptonuria, are divalent phenolic acids with very similar structures. Urine containing HGA is dark brown in color due to its oxidation. We recently reported a new oxidation method of HGA involving the addition of sodium hydroxide (NaOH) with sodium hypochlorite pentahydrate (NaOCl·5H2O), which is a strong oxidant. In the present study, we attempted to oxidize GA, which has a similar structure to HGA, using our method. We herein observed color changes in GA solution and analyzed the absorption spectra of GA after the addition of NaOH with NaOCl·5H2O. We also examined the oxidation reaction of GA using a liquid chromatography time-of-flight mass spectrometer (LC/TOF-MS). The results obtained indicated that GA solution had a unique absorption spectrum with a peak at approximately 500 nm through an oxidation reaction following the addition of NaOH with NaOCl·5H2O. This spectrophotometric method enables GA to be detected in sample solutions without expensive analytical instruments or a complex method.

Identifiants

pubmed: 32348369
doi: 10.1371/journal.pone.0232263
pii: PONE-D-19-27043
pmc: PMC7190133
doi:

Substances chimiques

Gentisates 0
Oxidants 0
Sodium Hydroxide 55X04QC32I
Sodium Hypochlorite DY38VHM5OD
Homogentisic Acid NP8UE6VF08
Aspirin R16CO5Y76E
2,5-dihydroxybenzoic acid VP36V95O3T

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0232263

Déclaration de conflit d'intérêts

This study was partly funded by Kaneka Corporation, Japan. Y. Ejima and K. Sogabe have an employment position to disclose. Y. Ejima is the Assistant Manager of Kaneka Corporation, which paid measurement expenses (LC/TOF-MS) to Kaneka Techno Research Corporation. K. Sogabe is the General Manager of Kaneka Techno Research Corporation. Y.T. - This work was supported by JSPS KAKENHI Grant Number JP19K16957. There are no patents, products in development or marketed products to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

J Clin Invest. 1970 Jul;49(7):1334-40
pubmed: 5432368
Sangyo Igaku. 1983 Sep;25(5):399-405
pubmed: 6668725
Br J Pharmacol. 1969 Sep;37(1):294-300
pubmed: 5343352
Microchem J. 2018 Mar;137:85-89
pubmed: 29180827
N Engl J Med. 2002 Dec 26;347(26):2111-21
pubmed: 12501223
Eur J Cancer Prev. 2004 Feb;13(1):53-63
pubmed: 15075789
Chem Pharm Bull (Tokyo). 2008 Apr;56(4):513-7
pubmed: 18379100
J Biol Chem. 1951 Sep;192(1):105-14
pubmed: 14917656
Molecules. 2010 Nov 08;15(11):7985-8005
pubmed: 21060304
J Pharm Biomed Anal. 2017 May 10;138:109-117
pubmed: 28192718
Biol Pharm Bull. 2004 May;27(5):706-9
pubmed: 15133250
Free Radic Biol Med. 1987;3(4):241-50
pubmed: 3121448
Biochim Biophys Acta. 2002 Aug 15;1572(1):123-32
pubmed: 12204341
Ther Drug Monit. 1980;2(4):365-72
pubmed: 7222191
J Biol Chem. 2010 Apr 9;285(15):11714-29
pubmed: 20145243
PLoS One. 2014 Jan 23;9(1):e86606
pubmed: 24466168
Clin Chem. 1973 Jul;19(7):770-3
pubmed: 4712525
Biochem J. 1951 Jan;48(1):xiv
pubmed: 14820810
Science. 1948 Sep 10;108(2802):281
pubmed: 17842717
Sci Rep. 2018 Jul 27;8(1):11364
pubmed: 30054539
Clin Chem. 1980 Jan;26(1):111-4
pubmed: 7356541
Arch Biochem Biophys. 1960 Jul;89:27-30
pubmed: 14422336
Eur J Pharm Sci. 2015 Jun 20;73:49-56
pubmed: 25840124

Auteurs

Sho Hosokawa (S)

Department of Medical Technology, Ehime Prefectural University of Health Sciences, Ehime, Japan.

Kenichi Shukuya (K)

Department of Medical Technology and Sciences, School of Health Sciences at Fukuoka, International University of Health and Welfare, Fukuoka, Japan.

Keisuke Sogabe (K)

Kaneka Techno Research Corporation, Hyogo, Japan.

Yasukazu Ejima (Y)

Kaneka Corporation, Vinyls and Chlor-Alkali Solutions Vehicle, Osaka, Japan.

Tatsuya Morinishi (T)

Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Kagawa, Japan.

Eiichiro Hirakawa (E)

Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Kagawa, Japan.

Hiroyuki Ohsaki (H)

Department of Medical Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan.

Tatsuo Shimosawa (T)

Clinical Laboratory Medicine, School of Medicine, International University of Health and Welfare, Chiba, Japan.

Yasunori Tokuhara (Y)

Department of Medical Technology, Ehime Prefectural University of Health Sciences, Ehime, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH